Health and Fitness Health and Fitness
Tue, November 2, 2010

Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Third Quarter 2010 Financial Results Call Set for November 9


Published on 2010-11-02 05:45:30 - Market Wire
  Print publication without navigation


Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Third Quarter 2010 Financial Results Call... -- VENLO, Netherlands, Nov. 2, 2010 /PRNewswire-FirstCall/ --

Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Third Quarter 2010 Financial Results Call Set for November 9

VENLO, Netherlands, Nov. 2,2010 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: [ QGEN ]) today announced the Webcast of its third quarter 2010 financial results call. The Webcast will take place at 9:30 a.m. EST on Tuesday, November 9, and will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.

What:

Webcast of QIAGEN's third quarter 2010 financial results call



When:

9:30 a.m. EST on November 9



Where:

The Webcast is accessible at [ www.qiagen.com/goto/ConferenceCall ]



How:

Log on to the Web at the address above




The corresponding presentation slides will be available for download in the investor relations section of QIAGEN's Web site at [ www.qiagen.com/goto/ConferenceCall ].


Contact:

Andreas Marathovouniotis, Russo Partners, (212) 845-4235




QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics.

QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at [ http://www.qiagen.com/ ].

(Minimum Requirements to listen to broadcast: The RealPlayer software, downloadable free from [ http://www.real.com/products/player/index.html ], or The Windows Media Player, downloadable free from [ www.microsoft.com ] and at least a 14.4Kbps connection to the Internet.  If you experience problems listening to the broadcast, send an email to [ prnwebcast@multivu.com ].)

SOURCE QIAGEN N.V.

[ Back to top ]

RELATED LINKS
[ http://www.qiagen.com ]

Featured Video

Other News Releases in Biotechnology

[ Optimer Pharmaceuticals Reports Third Quarter 2010 Financial Results ]

[ Pharmacyclics to Announce First Quarter Fiscal 2011 Results and Host a Conference Call on November 8, 2010 ]

[ Tolerx Forms Scientific Advisory Board to Advance Research in Type 1 Diabetes ]

Journalists and Bloggers

Visit [ PR Newswire for Journalists ] for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on [ The Digital Center ].

Contributing Sources